Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S M Swain

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Anti-Cancer Drugs|October 1, 1992
Therapy of patients with metastatic breast cancer with 5-fluorouracil, leucovorin and carboplatinL H Pai, S M Swain, D J Venzon, et al.
Cancer Research|July 15, 1987
Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancerS M Swain, R A Sorace, C S Bagley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of lifeS M Swain, J Rowland, K Weinfurt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumabS M Swain, A Schneeweiss, L Gianni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2018
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumabS M Swain, A Schneeweiss, L Gianni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 7, 2017
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumabS M Swain, A Schneeweiss, L Gianni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 1992
Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer InstituteA S Lichter, M E Lippman, D N Danforth, et al.
Clinical Transplantation|February 29, 2000
Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancerR P Gale, R E Park, R Dubois, et al.
ESMO Open|May 1, 2022
Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancerN D Modi, N O Danell, R N A Perry, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2017
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety studyS M Swain, M S Ewer, G Viale, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Anti-Cancer Drugs|October 1, 1992
Therapy of patients with metastatic breast cancer with 5-fluorouracil, leucovorin and carboplatinL H Pai, S M Swain, D J Venzon, et al.
Cancer Research|July 15, 1987
Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancerS M Swain, R A Sorace, C S Bagley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of lifeS M Swain, J Rowland, K Weinfurt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumabS M Swain, A Schneeweiss, L Gianni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2018
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumabS M Swain, A Schneeweiss, L Gianni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 7, 2017
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumabS M Swain, A Schneeweiss, L Gianni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 1992
Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer InstituteA S Lichter, M E Lippman, D N Danforth, et al.
Clinical Transplantation|February 29, 2000
Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancerR P Gale, R E Park, R Dubois, et al.
ESMO Open|May 1, 2022
Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancerN D Modi, N O Danell, R N A Perry, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2017
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety studyS M Swain, M S Ewer, G Viale, et al.
Pageof 8